Reimbursed Care Access in Poland

Currently classified as a strictly controlled psychotropic substance in the Polish schedules (group I‑P) with no authorised outpatient medical use outside of approved scientific or clinical research. Possession, production or distribution of psilocybin/psilocin-containing materials is criminalised under the Act on Counteracting Drug Addiction and the Minister of Health’s schedules; limited research uses are possible only under the statutory research authorisations and relevant sanitary/health office procedures. # #.

Currently classified within the national lists of controlled psychotropic substances and has no authorised medical reimbursement pathway in Poland outside of formally approved clinical trials. Therapeutic MDMA protocols (as being developed internationally) would require separate regulatory approval and a change in national programmes before routine reimbursed use; MDMA remains a listed psychotropic/controlled substance in the Polish regulatory annexes. # #.

Esketamine (marketed internationally as Spravato) is implemented in Poland under a dedicated reimbursed drug programme (program lekowy B.147) for treatment‑resistant depression (adult patients meeting narrow inclusion/exclusion criteria). The programme was launched in mid‑2023 and defines precise eligibility criteria (ICD‑10 codes, minimum episode duration, prior treatment failures, exclusion criteria such as certain personality/bipolar diagnoses, pregnancy, active substance dependence) and supervised administration schedules (induction twice weekly then maintenance weekly/biweekly), with treatment delivered in authorised centres participating in the B.147 programme. Patient access is via the Ministry of Health drug‑program mechanism and thus is publicly reimbursed under the conditions of that programme; because it is a program drug, detailed rules on centre contracting, patient selection and documentation are specified in the B.147 programme documentation. # #.

Ketamine is a legally authorised medicine in Poland for anaesthesia and certain acute indications (it is sold and distributed as a psychotropic drug for medical use) but its use as a repeated antidepressant infusion protocol is generally performed off‑label in private clinics and is not covered by standard public reimbursement (i.e., not integrated into an NFZ‑reimbursed psychiatric programme for depression). Clinics in Poland currently advertise ketamine psychiatric/infusion services in private practice; there are no national, routinely reimbursed ketamine infusion programmes for depression comparable to the esketamine B.147 program. Patients seeking ketamine for psychiatric indications therefore usually pay privately, and national professional guidance/standardisation for off‑label psychiatric ketamine remains limited. # # #.

Currently classified as a controlled psychotropic substance in Poland’s schedules and therefore not available for routine medical use outside approved research projects. N,N‑Dimethyltryptamine (DMT) appears in the Minister of Health annexes of controlled psychotropic substances; any therapeutic or clinical application would require formal authorisation and inclusion in an appropriate clinical/research programme. # #.

5‑MeO‑DMT is explicitly listed among controlled tryptamine derivatives in the Minister of Health regulation; it is therefore subject to the same restriction: no authorised medical/reimbursed outpatient use outside formally approved clinical research or specific state authorisations. Possession, distribution or use outside authorised channels is prohibited. #.

Currently classified under Poland’s controlled‑substance framework (either explicitly listed or catch‑all provisions for new psychoactive substances), and there is no authorised, reimbursed medical pathway for ibogaine outside of approved clinical research. Medical or therapeutic use of ibogaine would require specific regulatory approvals and is not part of routine reimbursed care. # #.

Ayahuasca preparations contain DMT and are treated under the national drug schedules that control DMT and related materials; there is no authorised medical/reimbursed pathway for ayahuasca outside of approved clinical research. Possession, distribution or administration outside legally authorised research would be unlawful. # #.

Mescaline is explicitly listed in the Minister of Health’s schedules as a controlled substance (3,4,5‑trimethoxyphenethylamine) and therefore is not available for routine medical/reimbursed use outside formally sanctioned clinical research or tightly regulated exceptions. Unauthorized possession, manufacture or distribution is prohibited. # #.

Many 2C‑series compounds (e.g., 2C‑I, 2C‑T‑2, 2C‑T‑7) are explicitly listed in the Polish psychotropic substances annexes and novel 2C‑derivatives are covered either directly or via the new psychoactive substances provisions; thus 2C‑class compounds are controlled and have no authorised medical reimbursement outside approved research. The national regulation both lists specific 2C substances and uses catch‑all rules for new psychoactive substances, restricting clinical availability to authorised research. # #.